Pyxis Oncology (PYXS) Gains from Investment Securities (2021 - 2025)
Pyxis Oncology (PYXS) reported Gains from Investment Securities of $900000.0 for Q4 2025, up 1600.0% year-over-year from $52941.2 in Q4 2024, and down 92.85% on a QoQ basis from $12.6 million in Q3 2025.
Pyxis Oncology (PYXS) has 5 years of Gains from Investment Securities data on file, last reported at $900000.0 in Q4 2025.
- Quarterly Gains from Investment Securities rose 1600.0% year-over-year to $900000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $842000.0 (up 256.78% YoY) and the FY2025 annual result came in at $12.5 million, up 28.39% from the prior year.
- Gains from Investment Securities eased to $900000.0 in Q4 2025 per PYXS's latest filing, from $12.6 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $14.3 million in Q4 2022 and bottomed at -$60000.0 in Q4 2024.
- The 5-year median for Gains from Investment Securities is $1.9 million (2022), against an average of $3.6 million.
- The widest annual swing landed in 2023, when Gains from Investment Securities plunged 100.36%; it then jumped 1600.0% in 2025.
- Tracing PYXS's Gains from Investment Securities over 5 years: stood at $5.9 million in 2021, then jumped by 141.22% to $14.3 million in 2022, then sank by 100.36% to -$52100.0 in 2023, then declined by 15.16% to -$60000.0 in 2024, then jumped by 1600.0% to $900000.0 in 2025.
- Per Business Quant, the three latest PYXS Gains from Investment Securities figures stand at $900000.0 (Q4 2025), $12.6 million (Q3 2025), and $2000.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Pyxis Oncology | 120.87 Mn | 103.97 Mn | 8.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 900,000.00 |
| Dec 31, 2025 | 900,000.00 |
| Sep 30, 2025 | 12.58 Mn |
| Sep 30, 2025 | 12.58 Mn |
| Mar 31, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | -60,000.00 |
| Dec 31, 2024 | -60,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 196,000.00 |
| Mar 31, 2024 | 196,000.00 |
| Dec 31, 2023 | -52,100.00 |
| Dec 31, 2023 | -52,100.00 |
| Sep 30, 2023 | 100,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Jun 30, 2023 | 5.30 Mn |
| Jun 30, 2023 | 5.30 Mn |
| Mar 31, 2023 | 5.71 Mn |
| Mar 31, 2023 | 5.71 Mn |
| Dec 31, 2022 | 14.30 Mn |
| Dec 31, 2022 | 14.30 Mn |
| Sep 30, 2022 | 18,000.00 |
| Sep 30, 2022 | 18,000.00 |
| Jun 30, 2022 | 2.82 Mn |
| Jun 30, 2022 | 2.82 Mn |
| Mar 31, 2022 | 6.17 Mn |
| Mar 31, 2022 | 6.17 Mn |
| Dec 31, 2021 | 5.93 Mn |
| Dec 31, 2021 | 5.93 Mn |
| Sep 30, 2021 | 3.53 Mn |
| Sep 30, 2021 | 3.53 Mn |